Tranzactioneaza Coherus Biosciences Inc (US.CHRS) - 1.265 USD (%) Tranzactioneaza
Indici
Descriere companie
Coherus BioSciences, Inc. (www.coherus.com) is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.